Amgen’s Repatha To Launch Next Week; Narrow Indication Mirrors Rival Praluent
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves PCSK9 inhibitor for use with statin therapy in adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease; drug priced at $14,100 annually for every two weeks administration.